✦ LIBER ✦

P2.136 Comparative efflcacy and safety of a novel carbidopa–levodopa product (IPX066) and Sinemet in advanced Parkinson's disease

✍ Scribed by A. Ellenbogen; R. Hauser; O. Omidvar; A. Hsu; M. O'Connell; S. Kell; S. Gupta

Book ID: 117753690
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 58 KB
Volume: 15
Category: Article
ISSN: 1353-8020
DOI: 10.1016/s1353-8020(09)70487-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Controlled release levodopa/carbidopa (S

Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease - an open evaluation of efficacy and safety

✍ Bulling, M.T. ;Wing, L.M.H. ;Burns, R.J. 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB

Crossover comparison of IPX066 and a sta

Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease

✍ Robert A. Hauser; Aaron L. Ellenbogen; Leo Verhagen Metman; Ann Hsu; Martin J. O 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 359 KB

## Abstract The objective of the study was to compare the pharmacokinetics, motor effects, and safety of IPX066, a novel extended‐release formulation of carbidopa‐levodopa, with an immediate‐release carbidopa‐levodopa formulation in advanced Parkinson's disease. We performed an open‐label crossover

P2.101 Efflcacy and safety of preladenan

P2.101 Efflcacy and safety of preladenant, a novel A2A receptor antagonist, as a levodopa adjunct in patients with moderate-to-severe Parkinson's disease

✍ R.A. Hauser; E. Pourcher; F. Micheli; V. Mok; M. Onofrj; S.B. Huyck; K.P. Wolski 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Long-term intraduodenal infusion of a wa

Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease

✍ D. Nilsson; L.-E. Hansson; K. Johansson; C. Nystrom; L. Paalzow; S.-M. Aquiloniu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 891 KB

A long-term, open-label study of levodop

A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: safety and motor-symptom endpoints

✍ Espay, A.J.; Odin, P.; Fernandez, H.H.; Hauser, R.A.; Standaert, D.G.; Lang, A.E 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Treatment of advanced Parkinson’s diseas

Treatment of advanced Parkinson’s disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage

✍ A. Munro Neville; Richard W. Parsons; Håkan Askmark; Dag Nyholm 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 101 KB